ArticleProtein & cell2017
Addressing challenges in the clinical applications associated with CRISPR/Cas9 technology and ethical questions to prevent its misuse.
Article in Protein & cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Application progress and biosafety challenges of gene editing and synthetic biotechnology in diagnosis, treatment and prevention of infectious diseases.Biosafety and health · 2025Review
- Similarity-based transfer learning with deep learning networks for accurate CRISPR-Cas9 off-target prediction.PLoS computational biology · 2025Article
- Crispr-SGRU: Prediction of CRISPR/Cas9 Off-Target Activities with Mismatches and Indels Using Stacked BiGRU.International journal of molecular sciences · 2024Article
- CRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine.Current gene therapy · 2024Review
- Using traditional machine learning and deep learning methods for on- and off-target prediction in CRISPR/Cas9: a review.Briefings in bioinformatics · 2023Review
- Attitudes towards genetic testing: The role of genetic literacy, motivated cognition, and socio-demographic characteristics.PloS one · 2023Article
- Nucleolus localization of SpyCas9 affects its stability and interferes with host protein translation in mammalian cells.Genes & diseases · 2022Article
- CRISPR therapy towards an HIV cure.Briefings in functional genomics · 2020Article
- Germline genome editing versus preimplantation genetic diagnosis: Is there a case in favour of germline interventions?Bioethics · 2020Article
- Efficient Generation of Pathogenic A-to-G Mutations in Human Tripronuclear Embryos via ABE-Mediated Base Editing.Molecular therapy. Nucleic acids · 2019Article
- Regenerative Medicine: A Review of the Evolution of Autologous Chondrocyte Implantation (ACI) Therapy.Bioengineering (Basel, Switzerland) · 2019Review
- Drug-release system of microchannel transport used in minimally invasive surgery for hemostasis.Drug design, development and therapy · 2019Article
- An Overview of the CRISPR-Based Genomic- and Epigenome-Editing System: Function, Applications, and Challenges.Advanced biomedical research · 2019Review
- Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Off-target predictions in CRISPR-Cas9 gene editing using deep learning.Bioinformatics (Oxford, England) · 2018Article
- Gene editing using CRISPR/Cas9: implications for dual-use and biosecurity.Protein & cell · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.